Compare TPC & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | CDTX |
|---|---|---|
| Founded | 1894 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | N/A | 2015 |
| Metric | TPC | CDTX |
|---|---|---|
| Price | $68.30 | $219.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $82.00 | ★ $119.44 |
| AVG Volume (30 Days) | 540.3K | ★ 2.1M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,103,323,000.00 | N/A |
| Revenue This Year | $24.11 | N/A |
| Revenue Next Year | $11.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.22 | N/A |
| 52 Week Low | $18.34 | $15.22 |
| 52 Week High | $77.00 | $220.46 |
| Indicator | TPC | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 88.62 |
| Support Level | $58.11 | $218.86 |
| Resistance Level | $63.60 | $220.46 |
| Average True Range (ATR) | 2.62 | 2.38 |
| MACD | 0.70 | 5.08 |
| Stochastic Oscillator | 98.02 | 99.41 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.